Literature DB >> 31137059

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

Athol Wells1, Anand Devaraj2, Elizabetta A Renzoni1, Christopher P Denton3.   

Abstract

Multidisciplinary diagnosis is now viewed as the diagnostic reference standard in interstitial lung disease (ILD). This process consists of the integration of the evidence base with clinical reasoning in the formulation of a diagnosis and requires input from clinicians, radiologists, and, in selected cases, histopathologists. In ILD associated with connective tissue disease (CTD-ILD), multidisciplinary evaluation is especially helpful when CTD is suspected but cannot be diagnosed using strict criteria. In this context, the integration of systemic clinical data, serologic information, and computed tomography and biopsy findings may allow CTD-ILD to be diagnosed. However, the value of multidisciplinary evaluation in CTD-ILD is not confined to diagnosis. The frequent coexistence of pulmonary processes other than ILD, including pulmonary vascular disease, extrapulmonic restriction, and airways disease, often has a major impact on symptoms and pulmonary function tests (PFTs). In this review, we highlight the value of multidisciplinary discussion (MDD) in reconciling clinical data, PFT, and imaging data in the accurate staging of disease severity, baseline prognostic evaluation, and the identification of progression of ILD. MDD also provides a means to combine the views of respiratory physicians and rheumatologists in formulating a treatment strategy. It is often possible to reach a robust view as to whether management should be driven by systemic disease, pulmonary disease, or both. When treatment needs to be introduced or modified for both systemic and pulmonary reasons, face-to-face discussion facilities the selection of therapeutic agents that are likely to be efficacious for both systemic and pulmonary diseases. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2019        PMID: 31137059     DOI: 10.1055/s-0039-1684020

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

Review 1.  [The multidisciplinary discussion-the gold standard in diagnosing interstitial lung diseases].

Authors:  Sabina Berezowska; Manuela Funke-Chambour; Alexander Pöllinger; Stephan C Schäfer
Journal:  Pathologe       Date:  2020-02       Impact factor: 1.011

Review 2.  Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.

Authors:  Soumya Chatterjee; Apostolos Perelas; Ruchi Yadav; Donald F Kirby; Amandeep Singh
Journal:  Clin Rheumatol       Date:  2022-10-21       Impact factor: 3.650

3.  Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir
Journal:  Respirology       Date:  2020-11-24       Impact factor: 6.424

4.  Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients.

Authors:  Dilek Tezcan; Abdullah Sivrikaya; Dilek Ergün; Halil Özer; Duygu Eryavuz Onmaz; Muslu Kazım Körez; Turan Akdağ; Semral Gülcemal; Muhammet Limon; Sema Yılmaz
Journal:  Clin Rheumatol       Date:  2021-06-14       Impact factor: 2.980

5.  Usefulness of digital velcro crackles detection in identification of interstitial lung disease in patients with connective tissue diseases.

Authors:  Andreina Manfredi; Giulia Cassone; Caterina Vacchi; Fabrizio Pancaldi; Giovanni Della Casa; Stefania Cerri; Lisa De Pasquale; Fabrizio Luppi; Carlo Salvarani; Marco Sebastiani
Journal:  Arch Rheumatol       Date:  2020-06-25       Impact factor: 1.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.